StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for KRMD yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $3.87 | $3.98 | +2.84% | 0.3M |
| 05-15 | $3.92 | $3.90 | -0.51% | 0.1M |
| 05-18 | $3.88 | $3.83 | -1.29% | 0.1M |
| 05-19 | $3.85 | $3.96 | +2.86% | 0.1M |
| 05-20 | $3.96 | $4.00 | +1.01% | 0.1M |
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2018 2018-12-31 | Q3 2018 2018-09-30 | Q2 2018 2018-06-30 | Q1 2018 2018-03-31 |
|---|---|---|---|---|
Revenue | $17.35M | $13.08M | $8.54M | $4.03M |
Operating Income | $1.16M | $1.60M | $1.12M | $501.13K |
Net Income | $910.57K | $1.27M | $879.15K | $403.43K |
EPS (Diluted) | $0.02 | $0.03 | $0.02 | $0.01 |
Total Assets | $10.55M | $10.58M | $10.26M | $9.36M |
Total Liabilities | $1.58M | $1.44M | $1.57M | $1.24M |
Cash & Equivalents | $3.74M | $3.65M | $3.42M | $4.03M |
Free Cash Flow OCF − CapEx | $1.18M | $1.16M | $862.60K | $-17.26K |
Shares Outstanding | 38.20M | 38.20M | 38.17M | 38.02M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.